The research team, led by investigators at Louisiana State University Health Sciences Center in New Orleans, set out to map how chronic alcohol exposure changes expression of orexin system-related genes across brain regions that mediate reward and stress. They focused on female Wistar rats at two distinct developmental stages, adolescence and adulthood, a choice motivated by growing epidemiological concern about alcohol misuse among women and girls. Recent data show that females are initiating drinking earlier, progressing to heavy drinking episodes faster, and arriving at emergency departments with alcohol-related problems at higher rates during early adolescence than males. Yet preclinical studies have historically underrepresented females, leaving gaps in understanding the biology that underlies these trends.

To model alcohol dependence in the laboratory, the researchers used chronic intermittent exposure to alcohol vapor, a well-established paradigm in which rats breathe vaporized alcohol for 14 hours per day. Adolescent females underwent four weeks of this exposure, beginning at postnatal day 30, while adult females were exposed for six weeks. Blood alcohol levels were monitored weekly and maintained within a target range of 150 to 250 milligrams per deciliter, with adolescents averaging 222 and adults 164 milligrams per deciliter. All behavioral testing and tissue collection occurred during acute withdrawal, six to eight hours after the vapor was turned off, when blood alcohol concentrations had returned to zero. This timing is critical, because it captures the brain in the state that dependent individuals experience when the drug is absent.

The behavioral readouts were carefully chosen to reflect two hallmark withdrawal symptoms. For the adolescent cohort, thermal nociception was measured with the Hargreaves test, in which a focused halogen light beam heats the hindpaw and the latency to withdraw it is recorded. Alcohol-exposed adolescent females showed a dramatically shorter withdrawal latency than air-exposed controls, a statistically robust indication of thermal hyperalgesia. For the adult cohort, anxiety-like behavior was assessed on the elevated plus maze, an apparatus with two walled arms and two open arms raised 50 centimeters above the floor. Anxious rodents avoid the open arms, and indeed the alcohol-exposed adult females spent significantly less time in the open arms than their alcohol-naive counterparts.

The molecular work relied on RNAscope, a sensitive in situ hybridization technique that detects messenger RNA transcripts in intact tissue sections with single-cell resolution. The researchers probed coronal sections containing the ventral tegmental area, the central amygdala, the nucleus accumbens shell, and the bed nucleus of the stria terminalis, quantifying puncta per cell with the open-source image analysis platform QuPath. In the ventral tegmental area, they simultaneously measured Hcrtr1, Th, a marker of dopamine neurons, and Fos, an activity-dependent gene. In the forebrain regions, they probed Hcrtr1, Drd1, and Fos. This multiplexed approach allowed the team to ask not only whether gene expression changed, but in which cell populations and in which circuits.

The headline result was strikingly specific. In both adolescent and adult alcohol-exposed females, the number of Hcrtr1-expressing neurons in the ventral tegmental area was elevated during withdrawal, whether expressed as a percentage of all neurons or as a percentage of dopamine neurons marked by Th. Roughly a quarter to a third of these Hcrtr1-positive cells were also Th-positive, indicating that a substantial fraction of the affected neurons are dopaminergic. Crucially, no comparable changes were detected in the central amygdala, nucleus accumbens shell, or bed nucleus of the stria terminalis, and Fos expression was unchanged everywhere. The orexin receptor alteration, in other words, is confined to the ventral tegmental area, distinguishing it from the broader stress-circuit adaptations documented in previous withdrawal studies.

Correlational analyses then linked this molecular change to behavior. In adolescent females, the number of Hcrtr1-positive ventral tegmental area neurons was negatively correlated with hindpaw withdrawal latency, meaning that rats with more receptor-expressing neurons pulled their paws away faster, consistent with heightened pain sensitivity. In adult females, the same measure correlated negatively with time spent in the open arms of the elevated plus maze, so more receptor expression tracked with more anxiety-like behavior. These correlations, with R-squared values of roughly 0.31 and 0.35 respectively, do not prove causation, but they tie a single molecular change to two distinct withdrawal phenotypes across two developmental windows.

Two additional experiments strengthened the case. First, quantitative PCR on tissue punches from the lateral hypothalamus, the source of orexin projections to the ventral tegmental area, revealed significantly elevated Hcrt messenger RNA in alcohol-exposed adolescent females compared with controls, indicating that the orexin peptide itself is upregulated upstream. Second, in a cohort of experimentally naive adult females, the researchers delivered orexin A directly into the ventral tegmental area through implanted cannulae and observed a rapid anxiogenic effect: treated rats spent less time in the open arms and made fewer open-arm entries than vehicle-treated controls, without any reduction in general locomotion. This demonstrates that orexin signaling in the ventral tegmental area is sufficient to produce an anxiety-like phenotype resembling withdrawal, even in animals never exposed to alcohol.

The orexin system, also known as hypocretin, is a neuropeptide network originating in the lateral hypothalamus that regulates arousal, feeding, reward seeking, and stress responses. Orexin A, one of its two principal peptides, binds both the orexin-1 and orexin-2 receptors, both of which are expressed in the ventral tegmental area. Activation of the orexin-1 receptor excites ventral tegmental area neurons through an endocannabinoid-mediated disinhibition mechanism, in which downstream synthesis of 2-AG engages presynaptic CB1 receptors on GABAergic terminals, reducing inhibitory tone onto projection neurons. In humans with alcohol dependence, circulating orexin concentrations rise during early withdrawal and decline gradually over weeks of abstinence, and orexin levels correlate positively with craving, depression, and anxiety, making the preclinical findings here directly relevant to the clinical picture.

The relationship between orexin and pain is more complicated. Intravenous orexin A can be analgesic in rodents through spinal mechanisms, and lateral hypothalamic stimulation reduces thermal nociception in neuropathic pain models via orexin-1 receptor signaling. Yet blocking orexin receptors also reduces stress-induced hyperalgesia in some paradigms, suggesting that the direction of the effect depends on receptor location and the model used. The current study does not resolve this tension, but it raises a concrete hypothesis: that orexin signaling specifically within the ventral tegmental area contributes to the heightened nociception of alcohol withdrawal. The authors note that future experiments testing whether pharmacological inhibition of ventral tegmental area orexin-1 receptors rescues thermal hyperalgesia, or whether local orexin administration produces hyperalgesia in naive animals, would establish causality directly.

Several caveats remain. The study measured messenger RNA, not protein, so whether the increased Hcrtr1 transcripts translate into more receptor protein and altered cellular function is unknown. The behavioral correlations were modest in magnitude and drawn from relatively small cohorts. And because orexin A engages both receptor subtypes, the anxiogenic effect of intra-ventral tegmental area orexin A could involve orexin-2 receptors as well as orexin-1. The authors also emphasize that all findings come from female rats, and whether the same relationships hold in males is an open question for ongoing work. Still, the convergence of region-specific gene expression changes, behavioral correlations across development, and a sufficiency experiment in naive animals makes a compelling case that the ventral tegmental area orexin system is a node worth targeting. If subsequent studies confirm causality, orexin-1 receptor antagonists, some of which are already in clinical development for sleep disorders and addiction, could offer a new pharmacological angle on the pain and anxiety that make alcohol withdrawal so punishing and relapse so likely.

Subject of Research: Orexin receptor signaling in the ventral tegmental area during alcohol withdrawal in female rats

Article Title: Chronic alcohol withdrawal-associated increases in VTA Hcrtr1 expression are associated with heightened nociception and anxiety-like behavior in female rats

Article References: Cruise, S., Secci, M. E., Kelley, L. K., Sharfman, N. M., Rodriguez-Graciani, K., Wills, T. A., Gilpin, N. W., & Avegno, E. M. (2025). Chronic alcohol withdrawal-associated increases in VTA Hcrtr1 expression are associated with heightened nociception and anxiety-like behavior in female rats. Advances in Drug and Alcohol Research, 5, Article 14199. https://doi.org/10.3389/adar.2025.14199

Image Credits: AI Generated

DOI: 10.3389/adar.2025.14199

Keywords: alcohol withdrawal, orexin, ventral tegmental area, Hcrtr1, nociception, anxiety-like behavior, female rats, hyperalgesia, lateral hypothalamus, adolescent alcohol exposure, substance use disorder, RNAscope